ClinicalTrials.gg
RecruitingNCT07306832Updated Oct 5, 2026

A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

A Phase 1 interventional study of Pivekimab Sunirine in Acute Myeloid Leukemia, sponsored by AbbVie. Recruiting at 14 sites in 7 countries. Open to participants aged 6 Months to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.
Updated Oct 5, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
6 Months to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies in Leukemia, Myeloid, Acute by AbbVie — 4 open to participants now, 10 under way, 3 of them phase 3. Leukemia, Myeloid, Acute · AbbVie.

Planned enrollment
29th of 32
18 · median 62
Started
2026
with 1 other
Phase 1
16 of 43
1 open now
Registered
42nd of 43
by date

Among the 43 studies in Leukemia, Myeloid, Acute by AbbVie, this one is the 29th largest by planned enrollment of the 32 interventional ones that give a count, is one of 2 that started in 2026, is one of 16 in phase 1, and was the 42nd registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

4 of the 43 studies in Leukemia, Myeloid, Acute by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 6 Months to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Leukemia, Myeloid, Acute by AbbVie, or all of them as a file.
02

Study summary

Acute myeloid leukemia (AML) is an aggressive blood cancer, withwith few options for participants who relapse after treatment or who don't respond to treatment. This study will assess the adverse events and how pivekimab sunirine moves through the body in pediatric participants with relapsed or refractory (R/R) AML.

Pivekimab sunirine is a drug being evaluated in the treatment of AML. This is an open label, single arm study, participants will be enrolled in 1 of the 3 cohorts based on their age and will receive pivekimab sunirine at a dose based on their weight. Around 18 pediatric participants with a diagnosis of AML will be enrolled in the study at approximately 30 sites around the world.

Participants will receive intravenous (IV) pivekimab sunirine alone. The total study duration is approximately 28 months.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, and checking for side effects.

03

Conditions studied

  • Acute Myeloid Leukemia

Keywords

  • Acute Myeloid Leukemia
  • Relapsed
  • Refractory
  • Pivekimab Sunirine
  • PVEK
  • Pediatric
04

Who can participate

Ages eligible
6 Months to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have confirmed acute myeloid leukemia (AML) meeting one of the following disease criteria:

    • Second or greater relapse. OR
    • Disease to second or subsequent (defined as resistant disease after at least one cycle of each treatment regimen).
  • Must have myeloid leukemic blasts that are CD123-positive by flow cytometry as determined by the treating institution.
  • Has >= 5% myeloid leukemic blasts in bone marrow at time of relapse or refractory disease and prior to Screening for this study.
  • Performance status by Lansky (\< 16 years old at evaluation) or (>= 16 years old at evaluation) score >= 50 or score \<= 2.
  • May have status of central nervous system (CNS)1, CNS2, or CNS3 disease without clinical signs or neurologic symptoms suggestive of CNS leukemia, such as facial nerve palsy, brain/eye involvement or hypothalamic syndrome. Participants receiving intrathecal therapy and no additional CNS-directed systemic therapy at study entry are eligible and may continue treatment as clinically indicated in accordance with institutional practice.
  • For those participants who have not reached the age of consent, parent or legal guardian with the willingness and ability to provide and participant willing and able to give assent, as appropriate for age and country.

Exclusion criteria

Exclusion Criteria:

  • Known cardiac disease.
  • Down syndrome.
  • Acute promyelocytic leukemia (APL) or juvenile myelomonocytic leukemia (JMML).
  • Symptomatic central nervous system (CNS3) disease
  • Prior history of any severity veno-occlusive disease/sinusoidal obstructive syndrome (VOD/SOS) of the liver.
  • Prior history of hematopoietic stem cell transplant within 6 months prior to Screening without evidence of active GvHD at the time of screening and the participant is off medications to treat or prevent either post-transplant (GvHD) or post-transplant rejection (except for a stable dose of ).
  • Have received prior Chimeric Antigen Receptor T-cell (CAR-T) therapy.
  • Any other known current requiring therapy.
  • Currently receiving anticancer therapy with antineoplastic intent, including radiotherapy, systemic therapy small molecules, monoclonal antibodies, other agents, or high-dose chemotherapy with the exception of intrathecal therapy.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Cohort 1: Pivekimab Sunirine Ages 2 to < 6 Years

    Participants will receive pivekimab sunirine, as part of the approximately 28 month study duration. If enrolled, subjects aged 6 months to less than 2 years will be included in Cohort 1

    Drug: Pivekimab Sunirine

  • Experimental
    Cohort 2: Pivekimab Sunirine Ages 6 to < 12 Years

    Participants will receive pivekimab sunirine, as part of the approximately 28 month study duration.

    Drug: Pivekimab Sunirine

  • Experimental
    Cohort 3: Pivekimab Sunirine Ages 12 to < 17 Years

    Participants will receive pivekimab sunirine, as part of the approximately 28 month study duration.

    Drug: Pivekimab Sunirine

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment-Emergent Adverse Events (TEAEs) Leading to Treatment Discontinuation

    Number of participants with protocol specified Treatment-Emergent Adverse Events (TEAEs) during and after treatment with pivekimab sunirine (PVEK). Severity of TEAEs will be graded according to the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: Up to Approximately 24 Months

  2. Maximum Observed Serum/Plasma Concentration (Cmax) of Intact Antibody-Drug Conjugate (ADC)

    Maximum observed serum/plasma concentration of intact ADC.

    Time frame: Up to Approximately 22 Months

  3. Cmax of FGN849 Payload

    Maximum observed serum/plasma concentration of FGN849 payload.

    Time frame: Up to Approximately 22 Months

  4. Area Under the Concentration-Time Curve (AUC) of Intact ADC

    Area under the concentration-time curve of intact ADC.

    Time frame: Up to Approximately 22 Months

  5. AUC of FGN849 payload

    Area under the concentration-time curve of FGN849 payload.

    Time frame: Up to Approximately 22 Months

  6. Time to Cmax (Tmax) of Intact ADC

    Time to Cmax of intact ADC.

    Time frame: Up to Approximately 22 Months

  7. Tmax of FGN849 Payload

    Time to Cmax of payload.

    Time frame: Up to Approximately 22 Months

Secondary outcomes

  1. Percentage of Participants Achieving Complete Remission (CR)

    CR is defined as Hematologic recovery: Absolute Neutrophil Count (ANC) \> 1.0 × 10\^9/L (\> 1,000/μL) and platelet count \> 100 × 10\^9/L (\> 100,000/μL); \< 5% bone marrow blasts; absence of circulating blasts; no evidence of extramedullary disease; no transfusions or support by exogenous growth factors (GCSF) within 7 days prior to response evaluation.

    Time frame: Up to Approximately 28 Months

  2. Percentage of Participants Achieving Composite Complete Remission (CR + complete remission with incomplete recovery [CRi])

    Percentage of participants achieving CR + CRi.

    Time frame: Up to Approximately 28 Months

  3. Percentage of Participants Achieving Composite Complete Remission (CR + complete remission with partial hematological [CRh])

    Percentage of participants achieving CR + CRh.

    Time frame: Up to Approximately 28 Months

  4. Duration of Complete Remission (DOCR)

    DOCR is defined as the first response of CR to the time of relapse or death from any cause, whichever comes first; for participants who did not relapse or die, the duration will be censored at the time of the last response assessment.

    Time frame: Up to Approximately 28 Months

  5. Duration of Composite Complete Remission (CR + CRi)

    Duration of composite complete remission (CR + CRi).

    Time frame: Up to Approximately 28 Months

  6. Duration of Composite Complete Remission (CR + CRh)

    Duration of composite complete remission (CR + CRh).

    Time frame: Up to Approximately 28 Months

07

Study locations

14 of 14 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Apr 2028, 23 months after the start.

Of 183 industry-sponsored phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 62. This study's planned 23 months is below that.

Counting every sponsor, half of 491 studies reached it within 49 months; a quarter within 31 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2025
First posted
Dec 29, 2025
StartActual
May 20, 2026
Primary completionEst.
Apr 2028
CompletionEst.
Mar 2030
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Children'S Healthcare Of Atlanta - Arthur M. Blank Hospital /ID# 275740 · Atlanta, United States
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    1 site added
    Show site
    • Children'S Healthcare Of Atlanta - Arthur M. Blank Hospital /ID# 275740 · Atlanta, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07306832
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Dec 29, 2025
Start date
May 20, 2026
Primary completion
Apr 2028 (estimated)
Completion
Mar 2030 (estimated)
Last update
Oct 5, 2026

Study contacts

ABBVIE CALL CENTER
Contact
abbvieclinicaltrials@abbvie.com
844-663-3742
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pivekimab sunirine

Start the discussion